17.2 Root Cause Analysis and CAPA Design

Root Cause Analysis and CAPA Design

• Problem Statement: Subject 204 received a 300 mg dose of investigational oncology drug instead of the protocol-mandated 200 mg dose under the protocol's weight-band dose table.
• Why #1: Why did the subject receive 300 mg? Because the research pharmacist prepared the infusion bag using a wrong weight-band category copied from an outdated worksheet rather than the current protocol dose table.
• Why #2: Why did the pharmacist use an incorrect weight-band category? Because the prescription worksheet provided by the study coordinator listed an outdated weight from a prior screening visit conducted two months earlier.
• Why #3: Why did the coordinator record an outdated weight on the prescription worksheet? Because the clinical electronic health record (EHR) contains multiple conflicting weight entries across inpatient and outpatient modules, and the coordinator selected the top entry without cross-referencing day-of-dosing vitals.
• Why #4: Why did the coordinator not confirm the day-of-dosing weight? Because the site clinic has no standardized chemotherapy order verification checklist requiring concurrent verification of day-of-treatment vitals before transmitting orders to pharmacy.
• Why #5 (Root Cause): The investigative site lacks an institutional Standard Operating Procedure (SOP) and dual-signature verification process governing investigational chemotherapy order transcription and pharmacy communication.

If the CRA had accepted the superficial explanation ("the coordinator made a clerical mistake; coordinator was verbally retrained"), the lack of an order verification process would inevitably lead to another dosing error when a different coordinator or pharmacist handled a subject.

The Ishikawa (Fishbone) Diagram

The Ishikawa diagram (also termed the cause-and-effect or fishbone diagram) provides a structured graphical framework for categorizing potential contributors to a complex failure. In clinical trial operations, causes are evaluated across six core operational domains:

• People: Personnel qualifications, lack of protocol-specific training, clinical coordinator turnover, investigator absence, staff fatigue, or language barriers.
• Process: Ambiguous site SOPs, overly restrictive protocol visit windows, lack of standardized worksheets, absent secondary verification steps, or cumbersome subject appointment handoffs.
• Equipment: Uncalibrated infusion pumps, freezer temperature excursions, broken centrifuges, malfunctioning ECG machines, or software access lockouts.
• Materials: Damaged central laboratory kits, expired collection tubes, ambiguous drug labeling, or missing investigational drug reconstitution diluents.
• Environment: Clinic room overcrowding, power outages, excessive ambient room temperature affecting drug stability, or courier delivery disruptions.
• Management / Governance: Inadequate Principal Investigator oversight, insufficient research coordinator staffing allocations, conflicting institutional priorities, or poor communication between clinic and research pharmacy.

Pareto Analysis (The 80/20 Rule)

Pareto analysis ranks categories by observed frequency or impact. The familiar 80/20 pattern is a heuristic, not an established rate for clinical trials. When auditing site compliance across a multi-center study, a CRA or central monitor aggregates all recorded deviations (e.g., missed visits, out-of-window labs, unrecorded concomitant medications). By categorizing and plotting deviations on a Pareto chart, the study team can identify the "vital few" operational bottlenecks (such as an overly complex 15-minute PK sampling window) versus the "trivial many" isolated mistakes.

Developing Effective Corrective and Preventive Action (CAPA) Plans

A critical failure mode in clinical research administration is the submission of vague, un-enforceable CAPA plans that fail to satisfy regulatory muster. Global health authorities (FDA, EMA, MHRA) routinely issue inspection findings for superficial CAPAs that state nothing more than "retrained staff on the protocol."

The Three Tiers of Remediation

To construct a well-supported CAPA, the CRA and investigative site must clearly differentiate between three distinct operational levels:

1. Correction (Immediate Remediation / Containment):

   • What action was executed immediately to contain the damage and resolve the isolated error?
   • Focuses strictly on the immediate subject, sample, or data point affected.
   • Examples: Administering a reversal agent or rescue therapy to an overdosed participant; obtaining emergency re-consent on the current IRB-approved form; quarantining suspect vials in an excursion-affected freezer; recalling a mislabeled specimen.

2. Corrective Action (Root Cause Elimination at the Site):

   • What permanent action will eliminate the identified root cause to prevent recurrence of that specific failure mode at the investigative site?
   • Focuses on modifying site procedures, tools, workflows, or oversight structures.
   • Examples: Revising the site's chemotherapy prescription workflow to mandate dual independent RN/PharmD calculation checks; reconfiguring the electronic scheduling software to lock appointments outside the allowable ±2-day protocol window; replacing an outdated laboratory requisition template with an automated pre-populated barcode system.

3. Preventive Action (Systemic Proactive Mitigation Across the Organization):

   • What proactive action will eliminate the root cause of potential non-compliance across other clinical trials, other investigative sites, or future research programs before errors occur?
   • Focuses on enterprise-wide, institutional, or sponsor-wide quality improvement.
   • Examples: The sponsor updating the master protocol template across an entire clinical development program to widen impractical visit windows; the academic medical center implementing a mandatory research credentialing policy for all clinical department chairs; updating the institutional CTMS to flag conflicting clinical trial appointments hospital-wide.

Applying SMART Criteria to CAPA Design

The SMART framework is a useful planning method, not an ICH-mandated acronym. Well-defined action items are:

• Specific: Defines precisely what operational action will be taken, which role is responsible, and which process is modified.
• Measurable: Establishes objective, quantifiable performance indicators to evaluate whether the intervention achieved its goal.
• Achievable: Operationally realistic given the site's staffing, technology infrastructure, and clinical resources.
• Relevant: Directly addresses the confirmed root cause identified during RCA, rather than an unrelated administrative symptom.
• Time-bound: Designates exact calendar deadlines for implementation, staff training, and subsequent effectiveness evaluations.

Official sources

Checked October 18, 2026: ICH E6(R3), Principles and Annex 1, ICH E8(R1).